Skip to main content

Table 1 Patient Characteristics

From: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

 

Arm A (n = 32)

Arm B (n = 31)

Total (n = 63)

 

n

Percent

n

Percent

n

Percent

Age

      

   Median

 

70

 

65

 

68

   Range

 

50-89

 

45-80

 

45-89

Race

      

   White

30

94%

28

90%

58

92%

   Black

1

3%

3

10%

4

6%

   Hispanic

1

3%

0

0%

1

2%

ECOG PS

      

   0

15

47%

17

55%

32

51%

   1

16

50%

12

39%

28

44%

   2

1

3%

2

6%

3

5%

Extent of Disease

      

   Measurable, Non-Osseous Disease Present

14

44%

13

42%

27

43%

   Evaluable, Osseous Disease Present

28

88%

30

97%

58

92%

   Evaluable, Non-Osseous Disease Present

13

41%

12

39%

25

40%

   Elevated PSA

32

100%

30

97%

62

98%

Metastatic Disease

      

   Lung

4

13%

4

13%

8

13%

   Liver

3

9%

3

10%

6

10%

   Bone

28

88%

29

94%

57

90%

   Bone Marrow

0

0%

1

3%

1

2%

   Pleura

1

3%

0

0%

1

2%

   Other

11

34%

9

29%

20

32%

Prior Treatment

      

   Orchiectomy

10

31%

7

23%

17

27%

   Prostatectomy

17

53%

15

48%

32

51%

   Other Surgery

19

59%

20

65%

39

62%

   Radiation Therapy

18

56%

20

65%

38

60%

   Hormonal Therapy

31

97%

29

94%

60

95%

   Biologic Response Modifier

4

13%

2

6%

6

10%